The Journal of dermatological treatment最新文献_第4页

The emerging applications of JAK inhibitors in dermatology - a systematic review. JAK抑制剂在皮肤病学中的应用综述。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-09-11 DOI: 10.1080/09546634.2026.2714664

Khalid M A Ahmed, Alaa I Alnajdawi, Nithikka Senthil Kumar, Syeda Mashala Jan, Katharine L Warburton

{"title":"The emerging applications of JAK inhibitors in dermatology - a systematic review.","authors":"Khalid M A Ahmed, Alaa I Alnajdawi, Nithikka Senthil Kumar, Syeda Mashala Jan, Katharine L Warburton","doi":"10.1080/09546634.2026.2714664","DOIUrl":"10.1080/09546634.2026.2714664","url":null,"abstract":"Background: Janus kinase (JAK) inhibitors are established treatments for selected dermatologic conditions, but their off-label use has expanded across refractory skin diseases.Methods: We systematically searched MEDLINE, Embase, and Web of Science from inception to October 1, 2025, for studies reporting off-label JAK inhibitor use in dermatologic disorders beyond approved or late-phase trial indications.Results: Of 9,182 records screened, 277 studies met the inclusion criteria, comprising 210 case reports, 55 case series, and 12 retrospective studies involving 764 patients. Owing to substantial clinical heterogeneity, findings were narratively synthesized using a structured disease-family framework. Off-label use most commonly involved lichenoid, neutrophilic, and granulomatous dermatoses. Overall, 725/764 (94.88%) patients experienced clinical benefit, including complete or near-complete response in 209/764 (27.35%) and significant or partial improvement in 516/764 (67.53%). Thirty-five patients (4.58%) showed no clinical change, and four (0.52%) experienced disease worsening. A total of 154 adverse events were reported, most commonly with tofacitinib; most were mild to moderate, although six were serious and 25 resulted in treatment discontinuation.Conclusion: JAK inhibitors demonstrate promising therapeutic potential across a broad spectrum of refractory dermatological diseases. The predominance of uncontrolled case-based evidence, heterogeneous dosing, and frequent combination therapy limits attribution of efficacy and safety to JAK inhibitor monotherapy. Prospective controlled studies are needed to better define their therapeutic role.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2714664"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148932384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality of life and patient-reported side effects of low-dose oral minoxidil in treating female pattern hair loss. 低剂量口服米诺地尔治疗女性型脱发的生活质量和患者报告的副作用。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-25 DOI: 10.1080/09546634.2026.2633066

Divija Sharma, Lillian Mo, Deep Patel, Austin Piontkowski, Candice Medina, Kelly Hawkins, Neda Shokrian, Benjamin Ungar

{"title":"Quality of life and patient-reported side effects of low-dose oral minoxidil in treating female pattern hair loss.","authors":"Divija Sharma, Lillian Mo, Deep Patel, Austin Piontkowski, Candice Medina, Kelly Hawkins, Neda Shokrian, Benjamin Ungar","doi":"10.1080/09546634.2026.2633066","DOIUrl":"10.1080/09546634.2026.2633066","url":null,"abstract":"Female pattern hair loss (FPHL) significantly affects women's well-being and quality of life (QoL), and low-dose oral minoxidil (LDOM) has increasingly gained attention as a convenient and effective treatment option. Although hypertrichosis is reported more often with LDOM than with topical formulations, patient perceptions and tolerance of this side effect remain poorly understood. We conducted a telephone survey at a single institution among women with FPHL currently taking or previously treated with LDOM for at least one month to evaluate treatment effectiveness, QoL, and side effect burden using the Women's Androgenetic Alopecia Quality of Life Questionnaire (WAA-QOL). Among 102 participants, the median duration of LDOM use was 12 months. Hair loss severity improved from a median score of 7 to 4 on a 10-point scale. Unwanted hair growth occurred in 71.6% of patients, most commonly on the face, arms, and legs; however, 93.2% did not consider it a reason to discontinue treatment, and most cases were mild or moderate. WAA-QOL scores improved significantly from baseline (67 to 39, p<0.001), with no predictors of unwanted hair growth identified. Overall, patients experienced clinical and QoL improvements, supporting a favorable patient-centered profile for LDOM.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2633066"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study. omalizumab治疗中国青少年慢性自发性荨麻疹的安全性和有效性：一项真实世界、前瞻性、多中心研究

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-07-13 DOI: 10.1080/09546634.2026.2694909

Yu Wang, Chengzhi Lv, Bin Yang, Zigang Xu, Lin Ma, Lixiong Gu, Zhiming Li, Niu Xiang, Xiaoyong Man, Juan Su, Liming Wu, Min Shu, Sirao Wang, Yujia Song, Yumeng Ren, Yuling Shi

{"title":"Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study.","authors":"Yu Wang, Chengzhi Lv, Bin Yang, Zigang Xu, Lin Ma, Lixiong Gu, Zhiming Li, Niu Xiang, Xiaoyong Man, Juan Su, Liming Wu, Min Shu, Sirao Wang, Yujia Song, Yumeng Ren, Yuling Shi","doi":"10.1080/09546634.2026.2694909","DOIUrl":"10.1080/09546634.2026.2694909","url":null,"abstract":"Objective: Chronic spontaneous urticaria (CSU) is a burdensome skin disorder that may remain inadequately controlled with standard H1 antihistamines (H1 AHs). Evidence on adolescents with CSU is limited. This 16-week study evaluated the safety and effectiveness of omalizumab in Chinese adolescents (≥12 to <18 years) with CSU who remained symptomatic despite H1 AH treatment (treatment period: 12 weeks; safety follow-up: 4 weeks).Methods: Safety assessments and routine clinical evaluations were performed. Effectiveness and quality of life were analyzed using the weekly urticaria activity score (UAS7), weekly itch severity score (ISS7), Urticaria Control Test (UCT), and Children's Dermatology Life Quality Index (CDLQI).Results: All 55 enrolled participants completed the study. Twenty-two participants (40.0%) experienced ≥1 treatment-emergent adverse event (TEAE). No serious adverse events, adverse events of special interest, deaths, or TEAEs leading to treatment discontinuation occurred. At Week 12, changes from baseline in ISS7 and UAS7 were -11.73 and -25.07, respectively; 70.9% participants achieved well-controlled CSU (UCT ≥ 12). The absolute mean change in CDLQI was -9.7 (relative improvement at Week 12: -81.5%).Conclusions: Omalizumab demonstrated a favorable safety profile and clinically meaningful effectiveness in Chinese adolescents with CSU who remained symptomatic despite H1 AH therapy and is a valuable option for this underrepresented population.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2694909"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physical activity as a potential nonpharmacologic strategy to prevent seborrheic dermatitis: a cohort study in the UK biobank. 体育活动作为预防脂溢性皮炎的潜在非药物策略：英国生物银行的一项队列研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-03-30 DOI: 10.1080/09546634.2026.2646001

Ziye Yang, Tong Zhang, Tongtong Zhang, Jiachen Liu, Rui Mao, Li Yang

{"title":"Physical activity as a potential nonpharmacologic strategy to prevent seborrheic dermatitis: a cohort study in the UK biobank.","authors":"Ziye Yang, Tong Zhang, Tongtong Zhang, Jiachen Liu, Rui Mao, Li Yang","doi":"10.1080/09546634.2026.2646001","DOIUrl":"10.1080/09546634.2026.2646001","url":null,"abstract":"Background: Seborrheic dermatitis (SD) is a chronic inflammatory skin disease with limited long-term treatment options. The association between physical activity and incident SD, as well as the potential mediating role of depressive symptoms, remains unclear.Objective: To investigate the association between physical activity and incident SD and to assess whether depressive symptoms mediate this relationship.Methods: Data from 396,903 participants in the UK Biobank were analyzed. Cox proportional hazards models were used to examine the association between physical activity and incident SD. Regression-based mediation analyses were performed to quantify the extent to which depressive symptoms mediated this association.Results: Physical activity above the recommended minimum (≥600 MET-min/week) was associated with a lower risk of incident SD. The greatest risk reduction was observed at 3-5 times the recommended level (1,800-3,000 MET-min/week; HR 0.80, 95% CI 0.71-0.90). Participants meeting criteria for healthy physical activity had a 28% lower risk of incident SD (HR 0.72, 95% CI 0.64-0.81). Mediation analyses showed that 17% of the protective association was explained by reduced depressive symptoms (indirect HR 0.83, 95% CI 0.77-0.88), while 16% was attributable to the direct effect of physical activity (direct HR 0.84, 95% CI 0.77-0.93).Conclusions: Physical activity may serve as a non-pharmacologic strategy for the prevention of SD, partly through alleviating depressive symptoms. The maximal benefit was observed at 3-5 times the recommended minimum activity level.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2646001"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147577235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Randomized evidence breadth and comparative maturity of systemic targeted therapies for prurigo nodularis: a time-aligned systematic review and network meta-analysis. 结节性痒疹的系统性靶向治疗的随机证据广度和比较成熟度：一项时间对齐的系统评价和网络荟萃分析。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-10-07 DOI: 10.1080/09546634.2026.2739090

Yanchen Liu, Haoran Hu, Linfeng Li

{"title":"Randomized evidence breadth and comparative maturity of systemic targeted therapies for prurigo nodularis: a time-aligned systematic review and network meta-analysis.","authors":"Yanchen Liu, Haoran Hu, Linfeng Li","doi":"10.1080/09546634.2026.2739090","DOIUrl":"10.1080/09546634.2026.2739090","url":null,"abstract":"Objectives: Randomized evidence for systemic targeted therapies in prurigo nodularis (PN) has expanded, but cross-trial differences limit valid comparison. We mapped randomized evidence and assessed comparative effects using exact Week-16 ≥ 4-point itch numerical rating scale response (NRS4).Methods: MEDLINE, Embase, CENTRAL, and Web of Science were searched through 14 August 2026. Studies with extractable randomized arm-level Week-16 NRS4 data were synthesized using a fixed-effect contrast-based network meta-analysis. Risk of bias was assessed with RoB 2 and confidence with CINeMA.Results: Twenty-four randomized studies were represented by 117 reports, but only seven cohorts (1,435 participants; 19 arms; 10 active nodes) contributed to the aligned network. Dupilumab (OR 4.04, 95% CI 2.42-6.75; low confidence) and global phase III nemolizumab (OR 5.81, 95% CI 3.81-8.86; low confidence) were effective versus placebo. The indirect nemolizumab-versus-dupilumab comparison was imprecise (OR 1.44, 95% CI 0.74-2.79; low confidence).Conclusions: Indirect evidence did not establish superiority of either biologic. The randomized evidence bases substantially exceeded the quantitatively comparable network, reflecting incomplete results availability and cross-trial differences.Registration: PROSPERO CRD420261401106.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2739090"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

'The good cancer': communicating a hypopigmented mycosis fungoides diagnosis to families. “好癌症”：将低色素蕈样真菌病诊断告知家属。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-10-12 DOI: 10.1080/09546634.2026.2742569

Emory Kim, Radhika Santhanagopalan, Lindsay C Strowd, Steven R Feldman

引用次数: 0

Does ANA positivity affect treatment outcomes in vitiligo? A clinical evaluation of 308-nm excimer light therapy. ANA阳性是否会影响白癜风的治疗结果？308 nm准分子光治疗的临床评价。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-12 DOI: 10.1080/09546634.2025.2612433

Ning Han, Dechao Jia, Cheng Chen, Jun Zhang, Yuling Yang, Ke Zhang, Mengsi Tan, Yu Peng, Yinghua Lan, Wei Zhang, Wen Zeng, Yu Wang, Hongguang Lu

{"title":"Does ANA positivity affect treatment outcomes in vitiligo? A clinical evaluation of 308-nm excimer light therapy.","authors":"Ning Han, Dechao Jia, Cheng Chen, Jun Zhang, Yuling Yang, Ke Zhang, Mengsi Tan, Yu Peng, Yinghua Lan, Wei Zhang, Wen Zeng, Yu Wang, Hongguang Lu","doi":"10.1080/09546634.2025.2612433","DOIUrl":"10.1080/09546634.2025.2612433","url":null,"abstract":"Objectives: Vitiligo is an autoimmune skin disorder characterized by melanocyte destruction and frequently associated with autoantibodies such as antinuclear antibodies (ANA). However, the clinical relevance of ANA positivity in relation to phototherapy response remains unclear. This study aimed to evaluate whether ANA positivity influences the efficacy and safety of 308-nm excimer light therapy in patients with vitiligo.Methods: In this cohort study, 86 patients with vitiligo received 308-nm excimer light therapy combined with topical agents, with oral mini-pulse prednisone added for active disease when necessary. Patients were stratified by ANA status, and therapeutic response was evaluated using the Vitiligo Area Scoring Index and standardized photographs over 6 months.Results: Of the 23 ANA-positive patients (26.7%), 19 (82.6%) had a titer of 1:100 and 4 (17.4%) had a titer of 1:320, with women comprising 73.9% of this group. ANA-positive lesions on the face and neck more frequently achieved moderate repigmentation (50-74%) but were less likely to reach excellent repigmentation (≥75%) compared with ANA-negative lesions. No significant differences were observed in cumulative treatment doses, adverse events, or the occurrence of new autoimmune conditions.Conclusions: In conclusion, this single-center cohort study suggests that ANA positivity does not significantly affect the efficacy or safety of 308-nm excimer light therapy in vitiligo, indicating that the impact of low-titer ANA may be limited.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2612433"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145954552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies. 克林霉素磷酸1.2%/阿达帕烯0.15%/过氧化苯甲酰3.1%凝胶治疗痤疮的长期疗效和耐受性：两项为期6个月的研究汇总结果

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-18 DOI: 10.1080/09546634.2026.2612873

Zoe D Draelos, Hilary Baldwin, Julie C Harper, Mahmoud Ghannoum, Linda Stein Gold, Emil A Tanghetti, Karol Wroblewski, Leon H Kircik

{"title":"Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies.","authors":"Zoe D Draelos, Hilary Baldwin, Julie C Harper, Mahmoud Ghannoum, Linda Stein Gold, Emil A Tanghetti, Karol Wroblewski, Leon H Kircik","doi":"10.1080/09546634.2026.2612873","DOIUrl":"10.1080/09546634.2026.2612873","url":null,"abstract":"Aim: Given the chronic nature of acne, two 6-month studies were conducted to evaluate the long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB)-the only approved triple-combination acne topical-and its effects on scarring/dyspigmentation in participants with moderate to severe acne.Materials and methods: Data were pooled from 2 identical, open-label, single-center studies conducted in participants (N = 50) aged ≥12 years with Investigator's Global Assessment (IGA) score of 3/4. Endpoints included change from baseline in IGA score, inflammatory/noninflammatory lesions, skin appearance (dryness, postinflammatory hyperpigmentation [PIH], postinflammatory erythema [PIE]), and scarring. Adverse events and tolerability (itching, burning, redness, swelling) were assessed.Results: At week 24, 67% of participants achieved treatment success, and significant reductions from baseline in inflammatory (88%) and noninflammatory (68%) lesions were observed (p < 0.001, both). Significant reductions in scarring (33%), investigator- and participant-assessed PIH (71%; 78%, respectively), and PIE (77%; 77%, respectively) were demonstrated (p < 0.001, all). Most participants (>70%) reported no tolerability issues throughout the studies. Seven adverse events occurred; 4 were related to CAB, and 3 led to study discontinuation (BPO allergy [n = 2], irritant contact dermatitis to BPO [n = 1]).Conclusions: These findings suggest that CAB is an appropriate and effective topical option for the long-term treatment of acne vulgaris.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2612873"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146000320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary on exploring the mechanism of differential responses to combination therapy in melasma: pigmentary versus mixed pigmentary-vascular types-a clinical study based on interaction analysis. 探讨黄褐斑联合治疗的差异反应机制：色素与混合色素-血管型-基于相互作用分析的临床研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-07-08 DOI: 10.1080/09546634.2026.2698365

Kanu Goyal, Riya Kalra, Aditi Nagpal

引用次数: 0

Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial. vunakizumab在不同疾病特征的中重度斑块性银屑病患者中的疗效：一项iii期试验的事后分析

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-06-23 DOI: 10.1080/09546634.2026.2641340

Jingjing Liu, Junyi Shao, Liyue Hou, Enci Mei, Lili He, Jingying Wang, Anqi Chen, Yi Zhang, Zhiming Li

{"title":"Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.","authors":"Jingjing Liu, Junyi Shao, Liyue Hou, Enci Mei, Lili He, Jingying Wang, Anqi Chen, Yi Zhang, Zhiming Li","doi":"10.1080/09546634.2026.2641340","DOIUrl":"10.1080/09546634.2026.2641340","url":null,"abstract":"Background: The efficacy of interleukin-17 inhibitors may be impacted by baseline psoriasis features.Objective: This post hoc analysis aimed to explore the efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis stratified by diverse disease features.Methods: This post hoc analysis used data from a phase III trial (NCT04839016); 690 patients with moderate-to-severe plaque psoriasis receiving vunakizumab (n = 461) or placebo (n = 229) were included.Results: The proportions of patients achieving Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and static physician's global assessment (sPGA) 0/1 responses at week (W)12 were significantly higher in the vunakizumab group than in the placebo group, regardless of the duration of psoriasis, PASI score, body surface area (BSA) involvement, and sPGA score. Similarly, at W4 and W8, treatment response rates were higher in the vunakizumab group than in the placebo group, regardless of the above-mentioned features. The same trend was also found at W24. However, treatment responses at W52 were almost not different between patients continuously receiving vunakizumab and those switching from placebo to vunakizumab, regardless of disease duration and disease severity.Conclusion: Vunakizumab shows satisfactory efficacy in patients with moderate-to-severe plaque psoriasis, regardless of psoriasis duration and severity.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2641340"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148304567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0